TECH BIO-TECHNE Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TECH

Price (delayed)

$347.69

Market cap

$13.42B

P/E Ratio

53.57

Dividend/share

$1.28

EPS

$6.49

Enterprise value

$13.65B

Sector: Healthcare
Industry: Biotechnology
Website: https://www.bio-techne.com/

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's ...

Highlights

The net income has soared by 167% YoY and by 8% from the previous quarter
TECH's EPS has surged by 165% year-on-year and by 8% since the previous quarter
TECH's P/E is 31% above its last 4 quarters average of 41.0 and 4.6% above its 5-year quarterly average of 51.2

Key stats

What are the main financial stats of TECH
Market
Shares outstanding
38.61M
Market cap
$13.42B
Enterprise value
$13.65B
Valuations
Price to earnings (P/E)
53.57
Price to book (P/B)
9.31
Price to sales (P/S)
17.64
EV/EBIT
43.04
EV/EBITDA
34.05
EV/Sales
17.97
Earnings
Revenue
$759.65M
EBIT
$317.21M
EBITDA
$400.95M
Free cash flow
$178.53M
Per share
EPS
$6.49
Free cash flow per share
$4.63
Book value per share
$37.34
Revenue per share
$19.71
TBVPS
$21.12
Balance sheet
Total assets
$2.05B
Total liabilities
$613.81M
Debt
$399.03M
Equity
$1.44B
Working capital
$436.47M
Liquidity
Debt to equity
0.28
Current ratio
5.14
Quick ratio
3.89
Net debt/EBITDA
0.57
Margins
EBITDA margin
52.8%
Gross margin
66.2%
Net margin
32.7%
Operating margin
22.8%
Efficiency
Return on assets
12.3%
Return on equity
18.3%
Return on invested capital
33%
Return on capital employed
16.3%
Return on sales
41.8%
Dividend
Dividend yield
0.37%
DPS
$1.28
Payout ratio
19.7%

TECH stock price

How has the BIO-TECHNE stock price performed over time
Intraday
3.11%
1 week
5.51%
1 month
12.82%
1 year
57.83%
YTD
9.49%
QTD
9.49%

Financial performance

How have BIO-TECHNE's revenue and profit performed over time
Revenue
$759.65M
Gross profit
$502.51M
Operating income
$173.19M
Net income
$248.29M
Gross margin
66.2%
Net margin
32.7%
The net income has soared by 167% YoY and by 8% from the previous quarter
BIO-TECHNE's net margin has surged by 157% YoY and by 5% QoQ
The company's operating income rose by 12% YoY and by 10% QoQ
BIO-TECHNE's operating margin has increased by 9% YoY and by 7% QoQ

Growth

What is BIO-TECHNE's growth rate over time

Valuation

What is BIO-TECHNE stock price valuation
P/E
53.57
P/B
9.31
P/S
17.64
EV/EBIT
43.04
EV/EBITDA
34.05
EV/Sales
17.97
TECH's EPS has surged by 165% year-on-year and by 8% since the previous quarter
TECH's P/E is 31% above its last 4 quarters average of 41.0 and 4.6% above its 5-year quarterly average of 51.2
The stock's price to book (P/B) is 69% more than its 5-year quarterly average of 5.5 and 43% more than its last 4 quarters average of 6.5
BIO-TECHNE's equity has increased by 23% YoY and by 4.2% from the previous quarter
The price to sales (P/S) is 88% higher than the 5-year quarterly average of 9.4 and 49% higher than the last 4 quarters average of 11.8
The revenue has grown by 3.5% YoY and by 2.8% from the previous quarter

Efficiency

How efficient is BIO-TECHNE business performance
TECH's return on assets has surged by 151% year-on-year and by 7% since the previous quarter
TECH's return on sales has surged by 130% year-on-year and by 4.5% since the previous quarter
BIO-TECHNE's ROIC has soared by 128% YoY and by 9% from the previous quarter
BIO-TECHNE's return on equity has surged by 126% YoY and by 3.4% QoQ

Dividends

What is TECH's dividend history
DPS
$1.28
Dividend yield
0.37%
Payout ratio
19.7%
Recent dividends

Financial health

How did BIO-TECHNE financials performed over time
The quick ratio has increased by 22% year-on-year and by 5% since the previous quarter
BIO-TECHNE's total liabilities has decreased by 18% YoY and by 5% QoQ
BIO-TECHNE's debt is 72% lower than its equity
TECH's debt to equity is down by 42% year-on-year and by 10% since the previous quarter
BIO-TECHNE's debt has decreased by 30% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.